Sana Biotechnology Introduces Hypoimmune Allogeneic CAR-T Cell…
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR-T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems